Companion diagnostics collaboration

Agreement formed for the development of companion diagnostic tests to support personalized medicine strategies.

Ventana Medical Systems Inc. (AZ, USA) and Boehringer Ingelheim (Ingelheim, Germany) have recently announced a collaboration for the development of companion diagnostic tests. The agreement will see the two companies developing tests for Boehringer Ingelheim oncology programmes.

Member of the Roche group, Ventana, will support Boehringer Ingelheim’s personalized medicine program for cancer drug development by providing its immunohistochemistry technology platform and experience in companion diagnostic development.

Klaus Dugi, Corporate Senior Vice President of Medicine at Boehringer Ingelheim stated, “We look forward to partnering with Ventana and accessing their significant capabilities and expertise in developing companion diagnostics that will complement our products to further advance the delivery of personalized healthcare solutions for patients.”

Over the past 10 years, Ventana has collaborated with more than 45 biopharmaceutical companies and is currently involved with over 150 projects for the development and commercialization of companion diagnostics. President of Ventana, Mara  Aspinall commented, “We are pleased that Ventana’s commitment to enable Personalized Healthcare for patients worldwide was recognized by Boehringer Ingelheim when they selected Ventana to be a companion diagnostics development partner for their oncology programmes.”

Source: Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests.